Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2009

View Archived Issues

Array BioPharma discovers oncolytic checkpoint kinase inhibitors

Case control analysis reveals reduced AD risk with IV immunoglobulin

Enhanced fibrinolytic potency seen with reprogrammed streptokinases

Riluzole modulates alcohol self-administration and withdrawal in preclinical studies

Liraglutide safe and effective in combination with metformin and rosiglitazone

Astellas Pharma reports first quarter FY2009 results

Rifaximin accepted for filing and granted priority review by FDA

BrainStorm receives funding for ALS research trials

Nanotherapeutics awarded NIAID contract to develop inhaled smallpox antiviral

PharmaGap reports NCI results from GAP-107-B-8 testing

Regado enrolls first patient in phase I trial of anticoagulant REG1 System

R-Tech Ueno completes enrollment in phase II UF-021 study

Phase III Urocidin trial cleared to continue by DMC

Loramyc marketing authorization granted in Switzerland

Wyeth to continue liver X receptor target program initiated by Karo Bio

T-type calcium channel antagonist TTA-A8 a clinical candidate for sleep disorders

Preclinical characteristics of antidiabetic candidate canagliflozin described

GSK presents preclinical data on novel S1P1 agonist, PPI-4955, at recent ACS meeting

Shire designs prodrugs of mu opioid receptor ligands for pain treatment

Monoamine neurotransmitter reuptake inhibitors described by NeuroSearch

Bayer Schering Pharma identifies novel compounds acting on Toll-like receptors

Wisconsin Alumni Research Foundation describes VDR ligands for skin conditions

Bayer Schering Pharma claims novel MR antagonists, PR and AR agonists

Enrollment in phase IIa trial of ALV-003 for celiac disease started

Gene-based medicine for refractory angina enters phase I/IIa clinical development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...